14. Huang YZ, McNamara JO (2010) Mutual regulation of Src family kinases and the neurotrophin receptor TrkB. J Biol Chem 285: 8207–8217. 15. Pearse RN, Swendeman SL, Li Y, Rafii D, Hempstead BL (2005) A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival. Blood 105: 4429–4436. 16. Jiffar T, Yilmaz T, Lee J, Hanna E, El-Naggar A, et al. (2011) KISS1 mediates platinum sensitivity and metastasis in head and neck squamous cell carcinoma. Oncogene. 17. Kupferman ME, Jayakumar A, Zhou G, Xie T, Dakak-Yazici Y, et al. (2009) Therapeutic suppression of constitutive and inducible JAK\STAT activation in head and neck squamous cell carcinoma. J Exp Ther Oncol 8: 117–127. 18. Li Z, Tan F, Thiele CJ (2007) Inactivation of glycogen synthase kinase-3beta contributes to brain-derived neutrophic factor/TrkB-induced resistance to chemotherapy in neuroblastoma cells. Mol Cancer Ther 6: 3113–3121. 19. Holcik M, Korneluk RG (2001) XIAP, the guardian angel. Nat Rev Mol Cell Biol 2: 550–556. 20. O’Connor L, Strasser A, O’Reilly LA, Hausmann G, Adams JM, et al. (1998) Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 17: 384–395. 21. Almeida S, Laco M, Cunha-Oliveira T, Oliveira CR, Rego AC (2009) BDNF regulates BIM expression levels in 3-nitropropionic acid-treated cortical neurons. Neurobiol Dis 35: 448–456. 22. Boisvert-Adamo K, Aplin AE (2008) Mutant B-RAF mediates resistance to anoikis via Bad and Bim. Oncogene 27: 3301–3312. 23. Schmelzle T, Mailleux AA, Overholtzer M, Carroll JS, Solimini NL, et al. (2007) Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis. Proc Natl Acad Sci U S A 104: 3787–3792. 24. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, et al. (2004) Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430: 1034–1039. 25. Geiger TR, Peeper DS (2005) The neurotrophic receptor TrkB in anoikis resistance and metastasis: a perspective. Cancer Res 65: 7033–7036. 26. Sengupta S, Mantha AK, Mitra S, Bhakat KK (2011) Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1. Oncogene 30: 482–493. 27. Eicher C, Dewerth A, Kirchner B, Warmann SW, Fuchs J, et al. (2011) Development of a drug resistance model for hepatoblastoma. Int J Oncol 38: 447–454. 28. Hoffmann AC, Wild P, Leicht C, Bertz S, Danenberg KD, et al. (2010) MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 12: 628–636. 29. Nemati F, Daniel C, Arvelo F, Legrier ME, Froget B, et al. (2010) Clinical relevance of human cancer xenografts as a tool for preclinical assessment: BDNF Contributes to Cisplatin Resistance example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts. Anticancer Drugs 21: 25–32. 30. Allen KE, Weiss GJ (2010) Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther 9: 3126–3136. 31. Poplawski T, Tomaszewska K, Galicki M, Morawiec Z, Blasiak J (2008) Promoter methylation of cancer-related genes in gastric carcinoma. Exp Oncol 30: 112–116. 32. Yague E, Armesilla AL, Harrison G, Elliott J, Sardini A, et al. (2003) P- glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem 278: 10344–10352. 33. Baker EK, Johnstone RW, Zalcberg JR, El-Osta A (2005) Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 24: 8061–8075. 34. Huo H, Magro PG, Pietsch EC, Patel BB, Scotto KW (2010) Histone Methyltransferase MLL1 Regulates MDR1 Transcription and Chemoresistance. Cancer Res 70: 8726–8735. 35. Kantharidis P, El-Osta A, deSilva M, Wall DM, Hu XF, et al. (1997) Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res 3: 2025–2032. 36. Sharma G, Mirza S, Parshad R, Srivastava A, Datta Gupta S, et al. (2010) CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin Biochem 43: 373–379. 37. Schulte JH, Schramm A, Klein-Hitpass L, Klenk M, Wessels H, et al. (2005) Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas. Oncogene 24: 165–177. 38. Kermani P, Hempstead B (2007) Brain-derived neurotrophic factor: a newly described mediator of angiogenesis. Trends Cardiovasc Med 17: 140–143. 39. Li Z, Thiele CJ (2007) Targeting Akt to increase the sensitivity of neuroblastoma to chemotherapy: lessons learned from the brain-derived neurotrophic factor/ TrkB signal transduction pathway. Expert Opin Ther Targets 11: 1611–1621. 40. Weinreb O, Amit T, Bar-Am O, Sagi Y, Mandel S, et al. (2006) Involvement of multiple survival signal transduction pathways in the neuroprotective, neuror- escue and APP processing activity of rasagiline and its propargyl moiety. J Neural Transm Suppl. pp 457–465. 41. Zhu N, Gu L, Li F, Zhou M (2008) Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells. Mol Cancer Ther 7: 1101–1109. 42. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, et al. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857–868. 43. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, et al. (2008) Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone- refractory prostate cancer in a preclinical mouse model. J Clin Invest 118: 3051–3064. PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e30246